Kornimate/medical-research-clean huggingface dataset:
fracture and fall prevention in elderly with osteoporosis

Conditions: Osteoporosis, Osteopenia

Summary: osteoporosis is a prevalent health concern among older adults and is associated with an increased risk of falls that can cause fracture, injury or mortality. identifying the factors related to falls occurring within this population is essential for the development of effective regimes for fall prevention. studies have shown that muscle quality and good posture alignments are critical for balance control in older adults. people are diagnosed with osteoporosis often combining with muscles weakness, and increased spine kyphosis leading vertebral, fractures and poor balance control, even falls. therefore, improving muscle quality, strengthening weak muscles and correcting postural alignment are essential elements for fracture and fall prevention in older adults with osteoporosis. the long-term objectives of this work are to prevent fracture and fall in older adults with osteoporosis by improving the function of degenerative muscles using exercise training.


Eligibility criteria:
osteopenia or osteoporosis group: inclusion criteria: * able to stand and walk for 5 minutes independently * having normal or corrected to normal vision * having age between \> 50 years * already have dexa and x-ray exam with osteopenia (-2.5 \< t-score \< -1.0) or osteoporosis (t-score \<-2.5) exclusion criteria: * being pregnant * sensory-motor deficits * inability of communication * lack of access to a telephone * t-score \<-2.5 combine with existing fracture control age-matched group: inclusion criteria: * able to stand and walk for 5 minutes independently * having normal or corrected to normal vision * having age between \> 50 years * already have dexa and x-ray exam without osteopenia or osteoporosis (t-score \> -1.0) exclusion criteria: * being pregnant * sensory-motor deficits * inability of communication * lack of access to a telephone * t-score \<-2.5 combine with existing fracture
high field magnetic resonance spectroscopy imaging for follow up of prostate cancer post brachytherapy implantation

Conditions: Prostatic Neoplasm

Summary: the purpose of this study is to establish the correct scanning parameters for obtaining good quality 3 tesla (3t) magnetic resonance spectroscopy images (mrsi) of the prostate gland before and after brachytherapy implantation for prostate cancer. three tesla mrsi may be a valuable additional diagnostic and follow-up investigation for prostate cancer patients.


Eligibility criteria:
inclusion criteria: * suitable candidate for prostate brachytherapy to treat prostate cancer * patient signs a study consent form exclusion criteria: * have received other radiotherapy for prostate cancer or hormone treatments * has contraindication to mrsi scanning * does not sign study consent form

Keywords: brachytherapy magnetic resonance spectroscopy
combination chemotherapy in treating young male patients with hodgkin's lymphoma

Conditions: Lymphoma

Summary: rationale: drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. giving combination chemotherapy may kill more cancer cells. purpose: this phase ii trial is studying the side effects and how well combination chemotherapy works in treating young male patients with hodgkin's lymphoma.

objectives: * determine the safety and efficacy of combination chemotherapy comprising vincristine, etoposide, cyclophosphamide, vinblastine, prednisone, and doxorubicin hydrochloride (vecopa) in pediatric male patients with previously untreated stage ii-iv classic hodgkin's lymphoma. * compare the effects of vecopa vs cyclophosphamide, vincristine, procarbazine hydrochloride, and prednisone (copp) in these patients. outline: this is a pilot, multicenter study. patients are stratified according to disease stage (ia/b\[e\], iia\[e\], iib, or iiia vs iib\[e\], iiia/b\[e\], iiib, or iva/b). * stratum 1 (stages ia/b\[e\], iia\[e\], iib, or iiia): patients receive oral prednisone on days 1-15, vincristine iv on days 1, 8, and 15, doxorubicin hydrochloride iv over 4 hours on days 1 and 15, and etoposide iv over 2 hours on days 2-6 (oepa). treatment repeats every 4 weeks for 2 courses. beginning at week 9, patients receive vecopa chemotherapy comprising oral prednisone on days 1-14 and 21-34, etoposide iv over 2 hours on days 1-3, doxorubicin hydrochloride iv over 2 hours on day 21, vinblastine iv and cyclophosphamide iv over 1 hour on days 1 and 21, and vincristine iv on days 8 and 29. patients then undergo radiotherapy. * stratum 2 (stages iib\[e\], iiia/b\[e\], iiib, or iva/b): patients receive 2 courses of oepa as in stratum 1 followed by 2 courses of vecopa (6-week courses). patients then undergo radiotherapy. after completion of study treatment, patients are followed periodically for at least 6 years. projected accrual: a total of 30 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of classic hodgkin's lymphoma (hl) * intermediate or advanced disease (stage i\[e\]-iv) * no lymphocyte-predominant hl * previously untreated disease patient characteristics: * male * no known hypersensitivity or contraindication to study drugs * no other concurrent malignancies * no severe concurrent diseases (e.g., immune deficiency syndrome) * no known hiv positivity prior concurrent therapy: * see disease characteristics * no prior chemotherapy or radiotherapy * more than 30 days since prior and no other concurrent investigational drugs * more than 30 days since prior and no concurrent participation in another clinical trial

Keywords: stage ii childhood hodgkin lymphoma stage iii childhood hodgkin lymphoma stage iv childhood hodgkin lymphoma stage i childhood hodgkin lymphoma childhood lymphocyte depletion hodgkin lymphoma childhood mixed cellularity hodgkin lymphoma childhood nodular sclerosis hodgkin lymphoma
bariatric surgery registry

Conditions: Obesity, Morbid

Summary: periodic analyses of our extensive database with regards to different surgical procedures for severe obesity and different obesity co-morbidities will be of benefit to our severely obese patients as well as to others world-wide.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of morbid obesity * have undergone a bariatric surgical procedure at the vcu medical center

Keywords: bariatrics
combined biological treatment and chemotherapy for patients with inoperable cholangiocarcinoma

Conditions: Cholangiocarcinoma

Summary: the purpose of this study is partly to continue the good experience the investigators have with chemotherapy and partly to optimize treatment of inoperable cholangiocarcinoma by adding a biological antibody to the treatment of patients with wild-type kirsten rat sarcoma viral oncogene homolog (kras).

cholangiocarcinoma is a relatively rare disease. in denmark approximately 150 patients are diagnosed each year. a small part of the patients can be offered surgery, but the operation will rarely be radical, and most patients with cholangiocarcinoma are therefore candidates for chemotherapy. in denmark the combination therapy of gemcitabine, oxaliplatin and capecitabine has been used in recent years. based on experience with gastrointestinal tumors, however, there seems to be an effect of new biological substances, including egfr antibodies. there are casuistic reports on the specific effect of a monoclonal antibody against egfr in cholangiocarcinoma. the effect of egf is mediated through an intracellular pathway involving the kras protein. it has been shown that a mutation of kras causes the egf system to be constantly activated. effect in patients with a kras mutation is therefore not to be expected. approximately 50% of the patients present this mutation.

Eligibility criteria:
inclusion criteria: * histologically verified adenocarcinoma arisen from gallbladder, extra or intrahepatic bile ducts or malignant cells consistent with the above and concomitant radiologic findings consistent with cholangiocarcinoma. * curative treatment presently discounted (surgery, stereotactic radiotherapy, etc.) * kras analyzed and found wild-type (wt) or mutated * ps 0-2 * evaluable disease according to recist criteria, i.e., the disease does not need to be measurable * haematology: * anc ≥ 1.5 x 10\^9/l * thrombocytes ≥ 100x10\^9/l * biochemistry: * bilirubinaemia ≤ 3 x upper normal value * alat ≤ 5 x upper normal value * creatinin ≤ upper normal value. if raised creatinin, the measured or calculated gfr must be at least 50% of the lower normal value. * fertile women must present a negative pregnancy test and use birth control during and 3 months after treatment. the following methods are considered safe birth control: birth control pills, coil, gestagen deposit injection, subdermal implantation, hormonal vagina ring, and transdermal deposit band-aid) * oral and written informed consent exclusion criteria: * chemotherapy within 4 weeks * radiotherapy within 4 weeks * immunotherapy within 4 weeks * other concomitant experimental treatment * known neuropathy ≥ grade 2 * serious congruous medical disease * other previous malignant disease within 5 years, excl. non-melanoma skin cancer and carcinoma in situ cervicis uteri * previous serious and unexpected reactions to fluoropyrimidine treatment * hypersensitivity to one or more of the active substances, auxiliary substances or fluoruracil * patients with interstitial pneumonitis or pulmonary fibrosis

Keywords: kras wild-type cholangiocarcinoma inoperable
clinical efficacy of axillary block in cervical radiculopathy

Conditions: Pain, Chronic

Summary: the primary endpoint of this study was to compare the clinical efficacy of axillary block in patients of cervical radiculopathy using 2 volumes of local anesthetics.

the interscalene brachial plexus block is an effective intervention for reducing postoperative pain but is related to side effects, suprascapular nerve block and a block of the axillary nerve have been introduced as alternatives to the interscalene brachial plexus for the control of postoperative pain. previous study demonstrated new method of axillary block using interfascial plane injection guided by ultrasoud. axillary block has been used widely for the relief of postoperative arm pain. recent study deomonstrated good pain relief when ultrasound guided interfascial plane injection was performed in patients with cervical radiuculopathy. there is no study showing clinical efficacy of interfascial plane injection of axillary block in patients of cervical radiculopathy.

Eligibility criteria:
inclusion criteria: * cervical foraminal stenosis * cervical central stenosis * cervical disc herniation * cervical spondylolisthesis * prominent arm pain rather than neck pain exclusion criteria: * infection * pregnancy * allergy to local anesthetic agents * previous cervical spine surgery * prominent neck pain rather than arm pain
the association between endometriosis, obesity and nesfatin1

Conditions: Endometriosis

Summary: the association between endometriosis, obesity and nesfatin1.

all women in this study were subjected to all of the following: 1. verbal consent was obtained. 2. history taking: 1. personal history. 2. menstrual history. 3. use of contraception. 4. use of any hormonal treatment in the three months prior to the laparoscopy. 5. history of infertility and its duration and type. 6. sexual history. 7. past history. 3. complete physical examination: general, abdominal and local gynecological examination. 4. complete preoperative workout for laparoscopy was done. 5. laparoscopy was done postmenstrual, during follicular phase. all patients gave an informed consent and were fasting for at least 8 hours prior to the laparoscopy, and general anesthesia was used for all patients. the pelvis and its structures were observed and checked for presence of endometriotic lesions (uterus, tubes, ovaries and ovarian fossae, uterosacral ligaments, douglas pouch, uterovesical pouch, broad ligaments and lateral pelvic walls). the endometriotic patients were then classified into stages i-iv according to the revised american fertility society scoring system for endometriosis. 6. venous samples for measurement of nesfatin-1 were taken by venipuncture from patients during the laparoscopy procedure immediately after initial evaluation and before any intervention. 7. biopsy from lesions suspected as endometriosis was taken during laparoscopy and sent to histopathology for confirmation. 8. the blood samples were centrifuged immediately after their collection at 5000 rpm for 10 min and serum samples were stored at -20 °c until analysis. patients and methods -67- 9. nesfatin-1 was measured by enzyme-linked immuno sorbent assay "elisa" technique using commercially available kits (boster biological technology human nesfatin-1 elisa kits, catalog number ek1138, usa) in the central labs of ain shams university hospitals.

Eligibility criteria:
inclusion criteria: * women in reproductive age group scheduled for laparoscopy for any indication. exclusion criteria: * women subject to any hormonal therapy in the last 3 months. * women with chronic endocrine disease like diabetes mellitus. * women diagnosed with pelvic inflammatory disease (pid). * severe medical disorder that prohibits the laparoscopic procedure, such as cardiovascular disease and pulmonary disease.
clinical study on macitentan, rt and tmz concurrent therapy followed by maintenance macitentan and tmz in newly diagnosed glioblastoma

Conditions: Glioblastoma

Summary: this is a prospective, single-center, open-label, 3+3 dose escalation phase 1 safety study. adults with newly diagnosed gbm or gliosarcoma will receive macitentan in addition to the standard of care treatment for gbm. the study consists of a screening period, a treatment period, and a 30-day safety follow up period. the treatment period includes 6 weeks of concurrent therapy (macitentan+rt+tmz), 4 weeks of monotherapy (macitentan) and 12 cycles of maintenance therapy (macitentan+tmz). the study will end when the last treated subject has completed study treatment and the 30-day safety follow-up period. the planned duration of the study is approximately 34-38 months depending on the number of dose levels and cohorts of subjects enrolled. subject participation in the study will be for approximately 16 months.


Eligibility criteria:
inclusion criteria: * subjects at least 18 years of age * histologically proven supratentorial gbm or gliosarcoma * use of effective contraception by women of childbearing potental. * use of effective contraception by fertile males with a female partner of childbearing potential. * interval of at least 3 weeks after biopsy or open surgery and able to begin study treatment. * result from a post-operative contrast-enhanced brain mri within 72 hours after surgery or biopsy. * adequate bone marrow function * karnofsky performance score of at least 70. exclusion criteria: * prior treatment for glioblastoma or gliosarcoma. * evidence of leptomeningeal spread of glibolastoma or gliosarcoma. * tumor foci below the tentorium or beyond the cranial vault. * evidence of recent hemorrhage on post-operative contrast enhanced brain mri (except hemosiderin, resolving hemorrhage changes related to surgery, presence of punctuate hemorrhage in tumor). * aspartate aminotransferase or alanine aminotransferase \> 3 times the upper limit of normal. * supine systolic blood pressure \< 100 mmhg or diastolic blood pressure \< 50 mmhg. * medical history of orthostatic hypotension. * international normalized ratio \> 1.5 on anticoagulant therapy, active bleeding on low molecular weight heparin, or chronic condition with a high risk of bleeding. * severe renal impairment. * severe hepatic impairment. * severe, active co-morbidity: (e.g. cardiac disease; respiratory disease; chronic hepatitis; hemtological and bone marrow diseases; severe malabsoprtion; human immunodeficiency virus). * no concurrent strong cyp3a4 inducers or inhibitors. * no investigational drug within 4 weeks of starting study treatment. * any life-threatening condition that could affect protocol compliance.

Keywords: glioblastoma
randomized study of the effect of decreased hyperinsulinemia on the ovulatory response to clomiphene citrate in obese women with polycystic ovary syndrome

Conditions: Hyperinsulinism; Polycystic Ovary Syndrome

Summary: objectives: i. determine whether reduction of serum insulin levels by metformin increases ovulatory response to clomiphene or spontaneous ovulation in obese women with polycystic ovary syndrome.

protocol outline: this is a randomized, double blind, placebo controlled, multicenter study. patients are randomized to one of two treatment arms. patients receive oral metformin (arm i) or oral placebo (arm ii) three times daily for 8 weeks. all patients who do not ovulate by day 28 receive oral clomiphene citrate daily on days 36-40.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- obese women with chronic anovulation due to polycystic ovary syndrome (pcos) must have oligoamenorrhea and hyperandrogenemia --prior/concurrent therapy-- at least 2 months since prior standard therapy (including over the counter drugs) at least 2 months since prior investigational agents --patient characteristics-- hematopoietic: hematocrit greater than 38% hepatic: liver function normal no clinically significant hepatic disease renal: no clinically significant renal disease creatinine less than 1.4 mg/dl no proteinuria cardiovascular: no clinically significant cardiac disease pulmonary: no clinically significant pulmonary disease hormonal: thyroid function normal prolactin normal fasting 17 alpha-hydroxy progesterone less than 200 mg/dl or no late onset adrenal hyperplasia 21 alpha-hydroxylase deficiency other: not pregnant negative pregnancy test fertile patients must use effective contraception no diabetes mellitus no clinically significant neurologic, psychiatric, infectious, neoplastic, or metabolic disease no clinically significant malignant disease except nonmelanomatous skin cancer at least 1 year since any prior drug abuse or alcoholism

Keywords: endocrine disorders hyperinsulinism polycystic ovarian syndrome rare disease
hospital interns psychological state during the covid-19

Conditions: COVID 19; Depression; Stress Disorders, Post-Traumatic

Summary: the mental health of the french population in response to covid-19 pandemic is of concern. health professionals are prone to more mental disorders due to their direct exposure to the pandemic consequences. indeed, compared to general population, health care workers face enormous in the current health situation, especially those who may be in contact with suspected or confirmed cases (risk of infection, inadequate protection, loss of control, lack of experience in managing the diseases, overwork, stigma, lack of support). thus, it seems interesting to describe the psychological state of hospital interns during this pandemic.


Eligibility criteria:
inclusion criteria: * being a des intern (occitanie-est) * being on internship as of november 1, 2020 exclusion criteria: - refusal to participate

Keywords: hospital interns
a study of sitagliptin in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy (0431-054)(completed)

Conditions: Diabetes Mellitus, Non-Insulin-Dependent

Summary: the clinical study determines the safety and efficacy of sitagliptin (mk0431) in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy.


Eligibility criteria:
inclusion criteria: * patients have type 2 diabetes mellitus on diet/exercise therapy exclusion criteria: * patients have type 1 diabetes mellitus
novel pathways to manage inflammation and atherosclerosis in dialysis patients: role of nicotinic acid

Conditions: Dialysis; Cardiovascular Disease; Atherosclerosis; Inflammation

Summary: patients with kidney failure on hemodialysis have an extremely high rate of cardiovascular disease including atherosclerotic cardiovascular disease. this, at least in part, is due to the chronic inflammatory status usually seen in these patients. here we try to see if treatment with extended release nicotinic acid (niaspan) can reduce their overall inflammatory burden (in general) and the atherosclerotic plaque inflammation (in particular).


Eligibility criteria:
inclusion criteria: * a signed consent form; * male or female, 18 years or older; * diagnosed with esrd, on maintenance hemodialysis for at least six (6) months; * subject must be able to understand and provide informed consent; * no known contraindications to therapy with nicotinic acid; * female subjects of childbearing potential must be willing to be on an acceptable form of birth control for the duration of the study and for two month after they have stopped taking the study drug. exclusion criteria: * any patient with a medical condition or taking any medications that would be contraindicated with the use of extended release niacin, such as active peptic ulcer disease; * history of severe allergic reactions to the study medication; * history of active infection or acute gouty attack within 2 weeks prior to enrollment; * known serological positivity for hiv, hbsag, or hcv ab; * hba1c \> 9; * total ck of more than three times of the upper limit of normal; * elevation of liver function tests at time of entry (ast and/or alt \> 2 times the upper limit of normal); * history of drug, alcohol, or chemical abuse within 6 months prior to enrollment; * history of malignancy except adequately treated in-situ cervical carcinoma, or adequately treated basal or squamous cell carcinoma of the skin; * history of an inflammatory disease such as sle, rheumatoid arthritis or ulcerative colitis; * patients currently on pharmacological doses of nicotinic acid; * patients receiving chronic anti-inflammatory therapy; * patients with average baseline hs-crp levels of \> 20 mg/l or \< 1 mg/l; * patients in whom fdg-pet/ct dual scans are contraindicated (e.g., pregnant patients or those with severe allergy to iv contrast; a pregnancy test will be performed in each female subject between 18 and 45 years of age prior to each scan)